Strategy and business model

We discover and develop peptide therapeutics with a focus on specialty gastrointestinal and metabolic diseases.

Zealand has a lean and agile organization, and we engage with partners across
the value chain, such as leading CROs and CMOs. We aim to retain full ownership and control of product candidates within rare diseases all the way to the market in selected geographies.

In diabetes and other broad indications, we will engage in development and/or commercial partnerships, the timing of which will depend on value optimization, with the aim of optimizing the progress of our programs and value.


Peptide research platform

Zealand is a world leader with 20 years’ experience in the discovery and development of peptide therapeutics.

Our success has largely come from our focus on the modification of endogenous gut peptide hormones, particularly glucagon, amylin, GLP-1, GLP-2 and GIP.

Today, we focus not only on optimizing the properties of endogenous hormones but also on exploring ion channels and other target classes.

Drug development

Zealand has built a worldclass late-stage development organization to support the fast progress of the clinical portfolio in line with our ambition to bring our own products to the market, retaining control and value inhouse.

Partnerships continue to be an important part of our business model and will enable us to move faster to market.


Zealand intends to commercialize our product candidates within rare diseases. The effort is commercially manageable, and we will retain full control and profitability. We will gradually build our commercial organization with a focus on the U.S. and Europe.

Business development

Zealand regards partnerships as pivotal to our success. Our Business Development team is responsible for identifying, structuring, negotiating and executing transactions with potential partners to build value and support Zealand’s ambition.